Oncotarget

Research Papers:

Increased mucosal expression of miR-215 precedes the development of neoplasia in patients with long-standing ulcerative colitis

Joel Pekow _, Katherine Meckel, Urszula Dougherty, Haider I. Haider, Zifeng Deng, John Hart, David T. Rubin and Marc Bissonnette

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:20709-20720. https://doi.org/10.18632/oncotarget.25065

Metrics: PDF 708 views  |   HTML 1078 views  |   ?  


Abstract

Joel Pekow1, Katherine Meckel1, Urszula Dougherty1, Haider I. Haider1, Zifeng Deng1, John Hart1,2, David T. Rubin1 and Marc Bissonnette1

1Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, Chicago, IL, USA

2Department of Pathology, University of Chicago Medicine, Chicago, IL, USA

Correspondence to:

Joel Pekow, email: jpekow@medicine.bsd.uchicago.edu

Keywords: miRNA; ulcerative colitis; neoplasia; colon cancer; predictive biomarker

Received: September 20, 2017     Accepted: March 21, 2018     Published: April 17, 2018

ABSTRACT

Identification of biological markers predicting the onset of neoplasia in patients with long-standing ulcerative colitis (UC) could allow for risk stratification in this population. In this study, we retrospectively identified subjects with chronic UC who developed colon neoplasia (n = 16) matched to UC patients who never developed neoplasia. RNA was extracted from archived colonic biopsies obtained at an interval of 1–2 years prior and 3–5 years prior to the onset of neoplasia. miRNA expression was assessed using Nanostring arrays in 12 subjects, and significantly up-regulated miRNAs were evaluated by real time pcr in the entire cohort of patients. Expression of miR-215 was also assessed in UC-associated colon cancers and compared to p53 expression. By array analysis, there were 17 significantly down-regulated and 7 significantly up-regulated miRNAs in subjects who later developed neoplasia. miR-215 was significantly up-regulated both 1–2 years prior to the onset of neoplasia (3.5-fold, p < 0.001) and 3–5 years prior to the onset of neoplasia (5.4-fold, p = 0.007). miR-215 expression was also increased in UC-associated colon cancers (5.3-fold, p = 0.03) and adjacent non-dysplastic UC tissue (6.2-fold, p = 0.02). p53 was expressed in 20% of patients prior to the onset of neoplasia and in 67% of UC-associated colon cancers, although was not correlated with miR-215 expression. Our data demonstrates that expression of miR-215 can discriminate patients who progressed to neoplasia from non-progressors as early as 5 years prior to the diagnosis of neoplasia, supporting that this and perhaps other miRNAs could serve as predictive biomarkers to risk stratify patients with chronic UC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25065